RxDoctor Payments Data

Kaleb Vaughn, DO

Internal Medicine · Pryor, OKNPI 1679070361

Payments from drug & device makers

$202in general payments, 2019–2025

Across 13 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$51
  • Pfizer$30
  • Abbott$23
  • Dexcom, Inc.$19
  • Merck$14
  • AbbVie$14
  • plus $52 from 4 others

What the payments were for

  • Food & beverage$202100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$202 in reported general payments places this provider in the 45th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$23,466
Medicare patients
90
Services billed
959

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide211$237,947
MounjaroTirzepatide177$196,905
EliquisApixaban179$183,094
Trelegy ElliptaFluticasone/Umeclidin/Vilanter112$83,179
JardianceEmpagliflozin40$57,654
XareltoRivaroxaban37$41,359
Tresiba Flextouch U-200Insulin Degludec48$28,358
EntrestoSacubitril/Valsartan16$23,462
FarxigaDapagliflozin Propanediol20$19,573
JanuviaSitagliptin Phosphate13$17,665
Fiasp FlextouchInsulin Aspart (Niacinamide)23$15,657
LinzessLinaclotide13$12,519
Breo ElliptaFluticasone/Vilanterol19$11,796
Combivent RespimatIpratropium/Albuterol Sulfate16$11,301
Lantus SolostarInsulin Glargine,hum.Rec.Anlog60$10,004

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$51$196,905177 claims
PfizerEliquis$30$183,094179 claims
Johnson & JohnsonXarelto$13$41,35937 claims
AbbVieLinzess, Synthroid$14$19,135109 claims
MerckJanuvia$14$17,66513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Pryor

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →